NTV Asset Management 13F: Adds $707K to Eli Lilly and (LLY) Stake
Key Points
- NTV Asset Management raised its stake in Eli Lilly and Company LLY by 611 shares to reach 31,222 shares valued at roughly $36.1 million in a filing on October 23, 2026.
- Eli Lilly and Company recently traded around $1,273.57 on October 24, 2026, sitting above its 50-day and 200-day moving averages as it approaches its next earnings report on October 29, 2026.
- Other institutional investors adjusted their holdings recently, with firms like True North Advisors and Symphony Financial also making changes to their positions.
Get Eli Lilly and Company text alerts
We text you when insiders, Congress, analysts or big funds move on $LLY.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Eli Lilly and Company alert may contain errors. Disclosures
In a Form 13F filing on October 23, 2026, NTV Asset Management disclosed that it boosted its stake in Eli Lilly and Company NYSE:LLY by 611 shares. The report reveals the firm owned 31,222 shares of the drugmaker at the end of the period, valued at about $36.1 million.
LLY
Eli Lilly and Company
What Changed in NTV Asset Management's Eli Lilly and Company Position
NTV Asset Management grew its holdings by 1.996% during the period, moving up from its previous total of 30,611 shares. The reported value of the position stood at $36,126,352. The filing outlines institutional positions held at the close of the quarter.
Other Institutional Activity in Eli Lilly and Company
Other institutional investors also adjusted their positions in Eli Lilly and Company around the same time. Wilmington Savings Fund Society, FSB reduced its holdings by 2,600 shares, ending with 25,292 shares worth about $29.3 million. Symphony Financial grew its holdings by 1,205 shares, ending with 7,802 shares worth about $9.2 million. Strategic Blueprint reduced its stake by 785 shares, leaving it with 12,911 shares valued at about $14.9 million. True North Advisors grew its holdings by 1,108 shares, ending with 4,217 shares worth about $4.9 million. Midwest Trust grew its holdings by 5,069 shares, ending with 73,312 shares worth about $84.8 million.
Eli Lilly and Company Stock Up 0.2%
Eli Lilly and Company recently traded around $1,273.57 on October 24, 2026, which was about equal to its closing price of $1,273.46 on the day of the filing. The stock sits well above both its 50-day and 200-day moving averages, and is down about 3.6% from its 52-week high of $1,321.21.
Recent Earnings
Eli Lilly and Company reports its next earnings on October 29, 2026.
Dividend
Eli Lilly and Company pays an annual dividend rate of $6.92 per share with a dividend yield of 0.53%.
Insider Buying and Selling at Eli Lilly and Company
Insiders completed several transactions prior to the filing. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, at an average price of $1,190.00 for a total of $5.95 million. Officer Donald A Zakrowski sold 2,000 shares on August 10, 2026, at $1,185.01 per share totaling about $2.37 million. Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, at $1,175.10 per share totaling roughly $7.64 million.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock ahead of the filing. JP Morgan maintained an Overweight rating with a $1,500.00 target on September 28, 2026. Morgan Stanley maintained an Overweight rating with a $1,430.00 target on October 7, 2026. Cantor Fitzgerald maintained an Overweight rating with a $1,440.00 target on October 8, 2026. RBC Capital reiterated an Outperform rating with a $1,500.00 target on October 12, 2026. Leerink Partners maintained an Outperform rating with a $1,316.00 target on October 21, 2026. The stock carries a consensus buy rating and a mean price target of $1,331.55 across 30 analyst opinions.
About Eli Lilly and Company
Eli Lilly and Company is a major healthcare company based in Indianapolis, Indiana. The firm discovers, develops, manufactures, and markets human pharmaceutical products globally. Its portfolio includes treatments across several major medical areas, supporting strong financial growth driven by high demand for its therapies.
Bottom Line
Investors will look toward the company's upcoming earnings release on October 29, 2026, for further updates on financial performance and pipeline progress. Institutional filings continue to provide visibility into how large managers position their portfolios around the stock.
Related Filing Alerts
Source: NTV Asset Management's 13F filing on $LLY (Oct 23, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts